PTC Therapeutics (PTCT) Misses Q3 EPS by 22c, Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results 
October 27, 2022 4:03 PM EDT- Total quarterly revenue of $217 million, representing 57% year-over-year growth -- 2022 DMD revenue guidance and low end of total revenue guidance increased -- Strategic financing with Blackstone with up to $1 billion of low-cost, low-dilution capital -- Pipeline of multiple innovative compounds continues to advance in clinical development -
SOUTH PLAINFIELD, N.J., Oct. 27, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2022.Â
... More